$ELOX
Eloxx Pharmaceuticals, Inc.

2017 Q2 Form 10-Q Financial Statement

#000114420417028931 Filed on May 22, 2017

View on sec.gov

Income Statement

Concept 2017 Q2 2017 Q1 2016 Q2
Revenue $0.00 $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $410.0K $220.0K $290.0K
YoY Change 41.38% -33.33% 141.67%
% of Gross Profit
Research & Development $2.595M $2.355M $410.0K
YoY Change 532.93% 308.54% -51.19%
% of Gross Profit
Depreciation & Amortization $7.000K $6.000K $10.00K
YoY Change -30.0% -70.0% -75.0%
% of Gross Profit
Operating Expenses $3.179M $2.632M $1.400M
YoY Change 127.07% 356.59% 45.83%
Operating Profit -$3.179M -$2.632M
YoY Change -46.16%
Interest Expense -$1.470M -$54.00K $30.00K
YoY Change -5000.0%
% of Operating Profit
Other Income/Expense, Net -$699.0K -$1.420M -$60.00K
YoY Change 1065.0% -291.89% -700.0%
Pretax Income -$2.010M -$2.066M -$1.430M
YoY Change 40.56% -40.62% 57.14%
Income Tax $0.00 $0.00 -$280.0K
% Of Pretax Income
Net Earnings -$3.878M -$2.678M -$1.150M
YoY Change 237.22% -13.03% 26.37%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$1.436M -$1.754M -$1.127M
COMMON SHARES
Basic Shares Outstanding 26.92M shares 20.74M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q2 2017 Q1 2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $30.00K $240.0K $810.0K
YoY Change -96.3% -84.31% -75.68%
Cash & Equivalents $13.36M $1.845M $810.8K
Short-Term Investments
Other Short-Term Assets $250.0K $30.00K $170.0K
YoY Change 47.06% -62.5% -57.5%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $280.0K $272.3K $982.6K
YoY Change -71.5% -82.98% -73.65%
LONG-TERM ASSETS
Property, Plant & Equipment $50.00K $60.15K $92.55K
YoY Change -45.98% -45.32% -50.23%
Goodwill $0.00
YoY Change -100.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $10.00K $10.00K $50.00K
YoY Change -80.0% -80.0% 0.0%
Total Long-Term Assets $5.565M $5.570M $8.243M
YoY Change -32.49% -37.84% -47.89%
TOTAL ASSETS
Total Short-Term Assets $280.0K $272.3K $982.6K
Total Long-Term Assets $5.565M $5.570M $8.243M
Total Assets $5.845M $5.842M $9.226M
YoY Change -36.64% -44.68% -52.8%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $191.6K $109.1K $90.31K
YoY Change 112.17% 81.91% -61.08%
Accrued Expenses $330.3K $158.0K $256.4K
YoY Change 28.83% -43.57% -37.27%
Deferred Revenue
YoY Change
Short-Term Debt $410.0K $260.0K $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.770M $1.057M $369.0K
YoY Change 650.7% 178.28% -52.6%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00 $99.73K
YoY Change -100.0% -100.0% -18.28%
Total Long-Term Liabilities $0.00 $0.00 $99.73K
YoY Change -100.0% -100.0% -18.28%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.770M $1.057M $369.0K
Total Long-Term Liabilities $0.00 $0.00 $99.73K
Total Liabilities $4.974M $3.257M $4.665M
YoY Change 6.62% -33.79% -36.29%
SHAREHOLDERS EQUITY
Retained Earnings -$121.8M -$119.5M -$115.6M
YoY Change 5.36% 7.88%
Common Stock $292.0K $269.2K $205.0K
YoY Change 42.48% 9.3%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $871.2K $2.585M $4.561M
YoY Change
Total Liabilities & Shareholders Equity $5.845M $5.842M $9.226M
YoY Change -36.64% -44.68% -52.8%

Cashflow Statement

Concept 2017 Q2 2017 Q1 2016 Q2
OPERATING ACTIVITIES
Net Income -$3.878M -$2.678M -$1.150M
YoY Change 237.22% -13.03% 26.37%
Depreciation, Depletion And Amortization $7.000K $6.000K $10.00K
YoY Change -30.0% -70.0% -75.0%
Cash From Operating Activities -$510.0K -$2.731M -$720.0K
YoY Change -29.17% 225.12% -70.25%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $74.00K $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 -$96.00K $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 300.0K 2.460M 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -510.0K -2.731M -720.0K
Cash From Investing Activities 0.000 -96.00K 0.000
Cash From Financing Activities 300.0K 2.460M 0.000
Net Change In Cash -210.0K -367.0K -720.0K
YoY Change -70.83% -56.31% -125.09%
FREE CASH FLOW
Cash From Operating Activities -$510.0K -$2.731M -$720.0K
Capital Expenditures $0.00 $74.00K $0.00
Free Cash Flow -$510.0K -$2.805M -$720.0K
YoY Change -29.17% 233.93% -75.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-119453761 USD
CY2016Q2 us-gaap Stockholders Equity
StockholdersEquity
4560658 USD
CY2017Q1 us-gaap Stockholders Equity
StockholdersEquity
2584731 USD
CY2016Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9225952 USD
CY2017Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5842205 USD
CY2016Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
171820 USD
CY2017Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
30309 USD
CY2016Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
956575 USD
CY2017Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
0 USD
CY2016Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
22310 USD
CY2017Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
0 USD
CY2017Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
121767033 USD
CY2016Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-115630059 USD
CY2016Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
810808 USD
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
241950 USD
CY2017Q1 svon Acquired Research And Development
AcquiredResearchAndDevelopment
5500000 USD
CY2016Q2 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
50770 USD
CY2017Q1 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
9800 USD
CY2017Q1 us-gaap Notes Payable Current
NotesPayableCurrent
256819 USD
CY2016Q2 us-gaap Notes Payable Current
NotesPayableCurrent
0 USD
CY2017Q1 us-gaap Licenses Revenue
LicensesRevenue
0 USD
CY2016Q1 us-gaap Licenses Revenue
LicensesRevenue
0 USD
CY2017Q1 us-gaap Costs And Expenses
CostsAndExpenses
341889 USD
CY2016Q1 us-gaap Costs And Expenses
CostsAndExpenses
4889005 USD
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-341889 USD
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4889005 USD
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-2066032 USD
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-3079113 USD
CY2017Q1 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
8979 USD
CY2016Q1 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
9501 USD
CY2017Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2075011 USD
CY2016Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3088614 USD
CY2017Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
0 USD
CY2016Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
0 USD
CY2017Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2075011 USD
CY2016Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3088614 USD
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.09
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.15
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23521726 shares
CY2017Q1 us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
0 USD
svon Deferred Rent
DeferredRent
22310 USD
svon Deferred Rent
DeferredRent
46572 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-141511 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-317009 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
18841 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-175430 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-90049 USD
CY2016Q2 us-gaap Assets Current
AssetsCurrent
982628 USD
CY2017Q1 us-gaap Assets Current
AssetsCurrent
272259 USD
CY2016Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
92554 USD
CY2016Q2 us-gaap Assets
Assets
9225952 USD
CY2017Q1 us-gaap Assets
Assets
5842205 USD
CY2016Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
90305 USD
CY2017Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
109146 USD
CY2016Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
256376 USD
CY2017Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
157993 USD
CY2016Q2 us-gaap Liabilities Current
LiabilitiesCurrent
368991 USD
CY2017Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1057474 USD
CY2016Q2 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
3240000 USD
CY2017Q1 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
2200000 USD
CY2017Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
60146 USD
CY2016Q2 svon Acquired Research And Development
AcquiredResearchAndDevelopment
8100000 USD
CY2016Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
99728 USD
CY2017Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0 USD
CY2016Q2 us-gaap Liabilities
Liabilities
4665294 USD
CY2017Q1 us-gaap Liabilities
Liabilities
3257474 USD
CY2016Q2 us-gaap Common Stock Value
CommonStockValue
204964 USD
CY2017Q1 us-gaap Common Stock Value
CommonStockValue
269206 USD
CY2016Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
119983399 USD
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20420608 shares
CY2016Q1 us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
667639 USD
CY2017Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-53997 USD
CY2016Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
0 USD
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
215146 USD
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
331611 USD
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
126743 USD
CY2017Q1 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0 USD
CY2016Q1 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
2980951 USD
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
576443 USD
CY2017Q1 us-gaap Change In Unrealized Gain Loss On Fair Value Hedging Instruments1
ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
0 USD
CY2016Q1 us-gaap Change In Unrealized Gain Loss On Fair Value Hedging Instruments1
ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
742253 USD
CY2017Q1 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0 USD
CY2016Q1 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
1000000 USD
CY2017Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2066032 USD
CY2016Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3479113 USD
CY2017Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2016Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-400000 USD
CY2016Q1 us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
0 USD
CY2017Q1 us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
0 USD
us-gaap Costs And Expenses
CostsAndExpenses
4059906 USD
us-gaap Costs And Expenses
CostsAndExpenses
9873467 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-4059906 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-9798467 USD
us-gaap Net Income Loss
NetIncomeLoss
-3789439 USD
us-gaap Net Income Loss
NetIncomeLoss
-7115276 USD
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
34263 USD
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
171984 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3823702 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7287260 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
0 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
0 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3823702 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7287260 USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.18
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.36
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
21644282 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20282054 shares
us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
305091 USD
us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
1967700 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-55962 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-371 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
995275 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1319986 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
614359 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1772530 USD
us-gaap Change In Unrealized Gain Loss On Fair Value Hedging Instruments1
ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
651484 USD
us-gaap Change In Unrealized Gain Loss On Fair Value Hedging Instruments1
ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
315862 USD
us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
2600000 USD
us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
1000000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4829439 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7515276 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1040000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-400000 USD
us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
0 USD
us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
149728 USD
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0 USD
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
5780951 USD
us-gaap Share Based Compensation
ShareBasedCompensation
79482 USD
us-gaap Share Based Compensation
ShareBasedCompensation
95008 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
34908 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
80588 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-139145 USD
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
0 USD
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
1152397 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
800000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1152397 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1809032 USD
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3334626 USD
svon Unrealized Gain Loss On Stock Rights
UnrealizedGainLossOnStockRights
315862 USD
us-gaap Increase Decrease In Deposits Outstanding
IncreaseDecreaseInDepositsOutstanding
-40970 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1416358 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2961429 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-568858 USD
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1525594 USD
svon Unrealized Gain Loss On Stock Rights
UnrealizedGainLossOnStockRights
651484 USD
svon Unrealized Gain Loss On Warrant Derivatives
UnrealizedGainLossOnWarrantDerivatives
305091 USD
svon Unrealized Gain Loss On Warrant Derivatives
UnrealizedGainLossOnWarrantDerivatives
1967700 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-75000 USD
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
5299 USD
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
6075 USD
svon Common Stock Proceeds To Warrants
CommonStockProceedsToWarrants
0 USD
svon Common Stock Proceeds To Warrants
CommonStockProceedsToWarrants
559261 USD
svon Common Stock Proceeds To Stock Rights
CommonStockProceedsToStockRights
0 USD
svon Common Stock Proceeds To Stock Rights
CommonStockProceedsToStockRights
142854 USD
svon Common Stock Proceeds To Warrants And Conversion
CommonStockProceedsToWarrantsAndConversion
0 USD
svon Common Stock Proceeds To Warrants And Conversion
CommonStockProceedsToWarrantsAndConversion
135701 USD
svon Preferred Dividends Accrued Not Yet Paid
PreferredDividendsAccruedNotYetPaid
-1167 USD
svon Preferred Dividends Accrued Not Yet Paid
PreferredDividendsAccruedNotYetPaid
-19003 USD
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
2600000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-1040000 USD
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
1000000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-400000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
47500 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
0 USD
us-gaap Proceeds From Sale Of Intangible Assets
ProceedsFromSaleOfIntangibleAssets
50000 USD
us-gaap Proceeds From Sale Of Intangible Assets
ProceedsFromSaleOfIntangibleAssets
0 USD
us-gaap Increase Decrease In Deposits Outstanding
IncreaseDecreaseInDepositsOutstanding
0 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2500 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
us-gaap Stock Issued1
StockIssued1
42597 USD
us-gaap Stock Issued1
StockIssued1
23615 USD
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
800000 USD
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 USD
CY2017Q1 svon Development Stage Enterprise Deficit Accumulated During Development Stages
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStages
119453761 USD
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12630037 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13201849 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
436363 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
svon Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod
28140 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
5840 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.22
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.83
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
62.93
svon Share Based Compensation Shares Authorized Under Stock Option Plans Exercised In Period Exercise Price
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisedInPeriodExercisePrice
0
svon Share Based Compensation Shares Authorized Under Stock Option Plans Cancelled In Period Exercise Price
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansCancelledInPeriodExercisePrice
0.83
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1917238 shares
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2319621 shares
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.29
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.59
svon Share Based Compensation Shares Authorized Under Stock Option Plans Granted Exercise Price
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansGrantedExercisePrice
0.22
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2291436 shares
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.62
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y7M6D
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
5119079 shares
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
6175 USD
CY2017Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
16276 USD
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P20M
CY2017Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
26920556 shares
CY2017Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2016Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2017Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
1040000 USD
CY2016Q3 us-gaap Business Acquisition Percentage Of Voting Interests Acquired
BusinessAcquisitionPercentageOfVotingInterestsAcquired
0.199 pure
CY2016Q3 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Liabilities Other
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther
99728 USD
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2017-03-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Registrant Name
EntityRegistrantName
Sevion Therapeutics, Inc.
dei Entity Central Index Key
EntityCentralIndexKey
0001035354
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Trading Symbol
TradingSymbol
SVON
CY2016Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2017Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26920556 shares
CY2017Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26920556 shares
CY2016Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20496385 shares
CY2016Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20496385 shares
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
79482 USD
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0 USD
us-gaap Dividends Common Stock
DividendsCommonStock
9501 USD
us-gaap Dividends Preferred Stock
DividendsPreferredStock
1167 USD
us-gaap Basis Of Accounting
BasisOfAccounting
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><font style="FONT-SIZE: 10pt">Note 1 - Basis of Presentation:</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The financial statements included herein have been prepared by Sevion Therapeutics, Inc. (the &#8220;Company&#8221;), without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;). Certain information and footnote disclosures normally included in financial statements prepared in accordance with United States generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended June 30, 2016 as subsequently amended.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In the opinion of the Company&#8217;s management, the accompanying unaudited condensed consolidated financial statements contain all adjustments, consisting solely of those which are of a normal recurring nature, necessary to present fairly its financial position as of March 31, 2017 and the results of its operations for the three months and nine months ended March 31, 2017 and cash flows for the nine months ended March 31, 2017.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Interim results are not necessarily indicative of results for the full fiscal year.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
us-gaap Change In Unrealized Gain Loss On Hedged Item In Fair Value Hedge1
ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
55550 USD
us-gaap Change In Unrealized Gain Loss On Hedged Item In Fair Value Hedge1
ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
0 USD
CY2017Q1 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
533516 USD
CY2016Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0 USD
CY2017Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
1417922 USD
CY2016Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0 USD
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
1417922 USD
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0 USD
CY2017Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
307774 USD
CY2016Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
307774 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
CY2017Q1 us-gaap Change In Unrealized Gain Loss On Hedged Item In Fair Value Hedge1
ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
55550 USD
CY2016Q1 us-gaap Change In Unrealized Gain Loss On Hedged Item In Fair Value Hedge1
ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
0 USD
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
74333 USD
us-gaap Convertible Preferred Stock Terms Of Conversion
ConvertiblePreferredStockTermsOfConversion
Each share of Series C Preferred Stock converted into 10 shares of Common Stock.
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1417922 USD
CY2017Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.40
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
svon Change In Fair Value Of Stock Right And Warrant Liability
ChangeInFairValueOfStockRightAndWarrantLiability
956575 USD
us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
307774 USD
CY2017Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.40
us-gaap Accretion Expense
AccretionExpense
45885 USD
us-gaap Accretion Expense
AccretionExpense
0 USD
us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
-55550 USD
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues
589066 USD
svon Debt Instrument Unamortized Discount Amortization Period
DebtInstrumentUnamortizedDiscountAmortizationPeriod
P8M
svon Convertible Notes Proceeds To Derivative Liability
ConvertibleNotesProceedsToDerivativeLiability
0 USD
svon Convertible Notes Proceeds To Derivative Liability
ConvertibleNotesProceedsToDerivativeLiability
589066 USD
CY2017Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
589066 USD

Files In Submission

Name View Source Status
0001144204-17-028931-index-headers.html Edgar Link pending
0001144204-17-028931-index.html Edgar Link pending
0001144204-17-028931.txt Edgar Link pending
0001144204-17-028931-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
svon-20170331.xml Edgar Link completed
svon-20170331.xsd Edgar Link pending
svon-20170331_cal.xml Edgar Link unprocessable
svon-20170331_def.xml Edgar Link unprocessable
svon-20170331_lab.xml Edgar Link unprocessable
svon-20170331_pre.xml Edgar Link unprocessable
v466378_10q.htm Edgar Link pending
v466378_ex10-3.htm Edgar Link pending
v466378_ex31-1.htm Edgar Link pending
v466378_ex31-2.htm Edgar Link pending
v466378_ex32-1.htm Edgar Link pending
v466378_ex32-2.htm Edgar Link pending